Key facts
- He Mu Biotechnology’s last known valuation is $10.8M (Jan 2023).
- It has raised $2.2M; the latest was Early Stage VC in Jan 2026.
- Notable investors include Innoangel Fund, Tsinghua Capital, Asia Green Fund, China-U.S. Green Fund, Hebei Airport Economic Zone Private Equity Fund Management — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for He Mu Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for He Mu Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About He Mu Biotechnology
Developer of animal mRNA vaccines in China designed to protect the development of the animal husbandry industry. The company's vaccines provide a comprehensive solution for pathogen detection and prevention and include more than ten animal mRNA vaccines for pigs, cattle and pets, enabling the animal husbandry industry in China to protect its livestock against viral diseases.
- Sector
- Business Products and Services (B2B)
- HQ
- Beijing, China
- Founded
- 2022
- Website
- hemubio.com/
- Ownership
- Privately Held (backing)
He Mu Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in He Mu Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on He Mu Biotechnology in its N-PORT filings yet. We sweep new filings monthly.